BAX and cancer: In the clinical setting, upregulation of antiapoptotic proteins (i.e., Bcl-2) and downregulation of proapoptotic proteins (i.e., Bax) are found to be associated with poor prognosis of cancer patients [11, 18], which supports a causal role of apoptosis inhibition in the occurrence of cancer cell drug resistance.